Introduction: Medicinal plants, believed to possess hypoglycemic and hypolipidemic potential namely, Gymnema sylvestre, Momorodica charantia, Murraya koenigii, Terminalia arjuna and Trigonella foenum graecum, were analysed for nutritional composition. Methods: Proximate analysis was done following the methods of AOAC. Available carbohydrate, β-carotene and minerals were analysed using spectrophotometer and atomic absorption spectrophotometer, respectively. One-way variance analysis was used to statistically analyse the variations in nutrient contents among the plants. Results: Moisture, crude protein, crude fibre, crude fat, ash, carbohydrate and energy content ranged between 10.86 - 91.81 , 2.81-25.60, 6.22-13.63, 0.48-7.41, 3.27-19.40, 52.87- 68.20 g/100 g and 292.78-400.17 Kcal/100 g on dry weight basis, respectively. Total soluble, reducing, non-reducing sugar and starch varied from 3.02-7.74, 1.74-4.78, 0.65-5.49 and 1.99-19.38 g/100 g, respectively. Neutral detergent fibre, acid detergent fibre, hemicellulose, cellulose and lignin ranged between 22.82-39.68, 1.98-20.69, 8.98- 31.19, 1.21-8.93, 0.72-12.50 g/100 g, respectively. Gymnema sylvestre had the highest concentration of β-carotene (7950 + 0.45 mg/100 g) and iron (37.21 + 0.50 mg/100 g), while Murraya koenigii had the highest copper (2.71 + 0.09 mg/100 g) and calcium concentration (42.76 + 0.43 mg/100 g). Chromium and zinc were highest in Momorodica charantia (2.93 + 0.22 mg/100 g) and Trigonella foenum graecum (3.61 + 0.46 mg/100 g), respectively. Significant difference was observed in the crude protein, crude fat, carbohydrate, energy, acid detergent fibre and lignin content of the medicinal plants.Conclusion: These medicinal plants can be considered as potential sources of protein, fat, dietary fibre, β-carotene and minerals for diabetic and dyslipidemic patients.

PURPOSE: The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emission tomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC), andMDAnderson (MDA) criteria for response assessment by Gallium 68-prostate-specific membrane antigen positron emission tomography-computed tomography (Ga68-PSMA PET-CT) in metastatic adenocarcinoma prostate cancer (mPCa) patients with biochemical progression.METHODS: Eighty-eight mPCa patients with pre and post treatment Ga68-PSMA PET-CTwere included. A ≥ 25% increase and ≥ 2 ng/ml above the nadir if prostate specific antigen (PSA) drop or ≥ 2 ng/ml above the baseline if PSA does not drop was considered as biochemical progression. RECIST 1.1 and MDA criteria for morphology and PERCIST and EORTC criteria for molecular response were investigated. Percentages of progressive disease (PD), partial response (PR), and stable disease (SD) were calculated. Chi-square test was used for statistical significance.RESULTS: Proportion of PD, SD, and PR by RECIST 1.1 and MDA criteria were 44 (50.57%), 39 (44.83%), 4 (4.6%), and 33 (39.76%), 48 (57.83%), 2 (2.41%) respectively. Proportion of PD, SD, and PR by PERCIST and EORTC criteria were 71 (80.68%), 11 (12.50%), 6 (6.82%), and 74 (84.09%), 8 (9.09%), 6 (6.82%) respectively. Chi-square test showed statistically significant (P < 0.05) higher proportion of progression detected by both molecular criteria as compare to both morphological criteria.CONCLUSION: We concluded that for Ga68-PSMA PET-CT response evaluation, molecular criteria performed better than morphological criteria in mPCa patient with PSA progression.
Adenocarcinoma ; Electrons ; Gallium ; Humans ; Membranes ; Positron-Emission Tomography ; Prostate ; Prostate-Specific Antigen ; Prostatic Neoplasms ; Response Evaluation Criteria in Solid Tumors

PURPOSE: The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emission tomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC), andMDAnderson (MDA) criteria for response assessment by Gallium 68-prostate-specific membrane antigen positron emission tomography-computed tomography (Ga68-PSMA PET-CT) in metastatic adenocarcinoma prostate cancer (mPCa) patients with biochemical progression. METHODS: Eighty-eight mPCa patients with pre and post treatment Ga68-PSMA PET-CTwere included. A ≥ 25% increase and ≥ 2 ng/ml above the nadir if prostate specific antigen (PSA) drop or ≥ 2 ng/ml above the baseline if PSA does not drop was considered as biochemical progression. RECIST 1.1 and MDA criteria for morphology and PERCIST and EORTC criteria for molecular response were investigated. Percentages of progressive disease (PD), partial response (PR), and stable disease (SD) were calculated. Chi-square test was used for statistical significance. RESULTS: Proportion of PD, SD, and PR by RECIST 1.1 and MDA criteria were 44 (50.57%), 39 (44.83%), 4 (4.6%), and 33 (39.76%), 48 (57.83%), 2 (2.41%) respectively. Proportion of PD, SD, and PR by PERCIST and EORTC criteria were 71 (80.68%), 11 (12.50%), 6 (6.82%), and 74 (84.09%), 8 (9.09%), 6 (6.82%) respectively. Chi-square test showed statistically significant (P < 0.05) higher proportion of progression detected by both molecular criteria as compare to both morphological criteria. CONCLUSION We concluded that for Ga68-PSMA PET-CT response evaluation, molecular criteria performed better than morphological criteria in mPCa patient with PSA progression.

INTRODUCTIONWe aim to study and elucidate the safety profile of the antiepileptic doses of gabapentin during pregnancy, and to evaluate gabapentin-induced murine fetotoxicity at different dose levels.

METHODSA total of 60 pregnant mice, divided into 12 groups of five mice each, were exposed to gabapentin in four different doses of 0 (control), 113, 226, or 452 mg/kg body weight per day, at three different gestational stages including early gestation (1-6 days), mid-gestation (7-12 days), and late gestation (13-17 days). The pregnant mice were euthanized on day 18 of gestation, and foetuses were examined for teratogenic manifestations. Their brains were dissected and examined for gross changes, malformations, histological changes, and quantitative protein estimation.

RESULTSFoetal resorptions were observed in all treated groups with gabapentin administration at early gestation (1-6 days), and mid-gestation (7-12 days). On the other hand, growth retardation along with stunting in size of live foetuses were observed in all the mid-gestation (7-12 days), and late gestation (13-17 days) treated groups. Various gross malformations were observed with all the three doses (113, 226, and 452 mg/kg body weight per day) when gabapentin was administered at mid-gestation (7-12 days). The same trends were confirmed by gross and microscopic examination of brains along with quantitative protein estimation.

CONCLUSIONGabapentin should not be prescribed during pregnancy, as no therapeutic dose of gabapentin is safe during this period as far as the foetal well-being is concerned.

Abnormalities, Drug-Induced ; Amines ; adverse effects ; Animals ; Anticonvulsants ; adverse effects ; Body Weight ; Congenital Abnormalities ; prevention & control ; Cyclohexanecarboxylic Acids ; adverse effects ; Dose-Response Relationship, Drug ; Female ; Mice ; Mice, Inbred ICR ; Models, Chemical ; Pregnancy ; Pregnancy, Animal ; drug effects ; Teratogens ; gamma-Aminobutyric Acid ; adverse effects

The inhibitory activity of ent-norsecurinine alkaloid was evaluated against spore germination of some plant pathogenic fungi (Curvularia maculans, Curvularia species, C. palliscens, Colletotrichum gloeosporioides, Colletotrichum species, Alternaria solani, A. brassicae, Fusarium udum, Helminthosporium echinoclova and H. penniseti). It inhibited spore germination of all the test fungi. C. maculans, C. species, and C. palliscens were the most sensitive as complete inhibition of spore germination was observed at 1000 ppm. A. solani was not inhibited by this chemical.
Alternaria ; Brassica ; Colletotrichum ; Fungi* ; Fusarium ; Germination* ; Helminthosporium ; Plants ; Spores*